Clinical Trial Detail

NCT ID NCT02401542
Title Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma (FIERCE-21)
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Rainier Therapeutics
Indications

ureter transitional cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

urethra transitional cell carcinoma

Therapies

Docetaxel + Vofatamab

Vofatamab

Docetaxel

Age Groups: adult senior

Additional content available in CKB BOOST